EMA — authorised 2 June 2017
- Application: EMEA/H/C/004246
- Marketing authorisation holder: bene-Arzneimittel GmbH
- Local brand name: Elmiron
- Indication: Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.
- Status: approved